REVOLUTION MEDICINES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.96 USD | +1.78% |
|
+2.98% | +25.38% |
Chart calendar Revolution Medicines, Inc.
f255f3a031d64b9521a027a362e9379.Phv9HsWkmlFN9SbxAOvp0h6JdP60oI6xIT68q1itNR4.TiKYJoD0_zh_zQupY6LasG_FG5WG597wbFLVhhbUeVdLeZh96P3PYQiEVQ~8d919688cefb0a39a11827d963f18bac
Upcoming events on Revolution Medicines, Inc.
Past events on Revolution Medicines, Inc.
| 16/04/2024 20:30 | Stifel Virtual Targeted Oncology Days Conference |
| 11/04/2024 18:30 | Needham Healthcare Conference |
| 09/04/2024 22:35 | American Association for Cancer Research Meeting - Abstract Number: 6585 |
| 09/04/2024 21:00 | American Association for Cancer Research Meeting - RMC-6236, a RAS(ON) Multi-Selective Tri-Complex I |
| 09/04/2024 17:00 | American Association for Cancer Research Meeting - Abstract Number: 4709/2 |
| 08/04/2024 21:30 | American Association for Cancer Research Meeting - Abstract Number: 3340/28 |
| 08/04/2024 17:00 | American Association for Cancer Research Meeting - Abstract Number: 1927/5 |
| 08/04/2024 17:00 | American Association for Cancer Research Meeting - Abstract Number: 1924/2 |
| 07/04/2024 21:45 | American Association for Cancer Research Meeting - Abstract Number: ND03 |
| 07/04/2024 21:30 | American Association for Cancer Research Meeting - Abstract Number: 581/4 |
| 06/03/2024 19:10 | TD Cowen Health Care Conference |
| 26/02/2024 21:30 | Q4 2023 Earnings Call |
| 25/02/2024 | Q4 2023 Earnings Release After hours |
| 07/02/2024 20:00 | Guggenheim Healthcare Talks Biotechnology Conference |
| 09/01/2024 19:15 | JPMorgan Healthcare Conference |
| 08/11/2023 16:00 | Extraordinary Shareholders Meeting - M&A Vote |
| 06/11/2023 21:30 | Q3 2023 Earnings Call |
| 06/11/2023 21:05 | Q3 2023 Earnings Release |
| 22/10/2023 17:30 | European Society for Medical Oncology Congress |
| 22/10/2023 07:30 | European Society for Medical Oncology Congress - Abstract Number 6520 |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 50,0 50,8 -1.43% | 43,0 51,0 -15.66% | 29,4 28,7 2.35% | 35,4 27,9 26.79% | 11,6 11,8 -2.05% | 4,62 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 0,00 - | -108 -106 -2.33% | -185 -173 -7.04% | -253 -263 3.72% | -481 -424 -13.47% | -590 |
|
EBIT Million USD | Released Forecast Spread | -54,1 -48,3 -11.97% | -111 -103 -7.99% | -188 -181 -3.61% | -258 -269 4.04% | -487 -433 -12.56% | -589 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -52,0 -49,7 -4.75% | -109 -99,9 -8.63% | -187 -182 -2.99% | -249 -265 5.88% | -440 -395 -11.25% | -520 |
|
Net income Million USD | Released Forecast Spread | -61,9 -55,5 -11.44% | -110 -101 -9.72% | -187 -183 -2.45% | -249 -262 5.11% | -436 -392 -11.32% | -516 |
|
EPS USD | Released Forecast Spread | -1,05 -1,43 26.41% | -2,01 -1,83 -10.04% | -2,57 -2,52 -2.01% | -3,08 -3,28 6.06% | -3,86 -3,48 -10.99% | -3,19 |
| Announcement Date | 30/03/20 | 02/03/21 | 28/02/22 | 27/02/23 | 26/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 9,46 8,99 5.23% | 7,58 10,3 -26.43% | 9,12 7,02 29.89% | 3,36 6,34 -47.04% | 15,3 7,80 96.47% | 7,01 2,94 138.77% | 3,82 1,56 144.74% | 0,00 0,86 - | 0,74 1,20 -38.17% | 0,67 | 0,67 | 0,67 | 0,67 | 0,23 |
|
EBITDA Million USD | Released Forecast Spread | -178 | -160 | -163 | -168 | -171 | -177 | ||||||||
|
EBIT Million USD | Released Forecast Spread | -52,9 -46,4 -13.95% | -57,9 -56,2 -3.1% | -62,1 -62,6 0.87% | -76,5 -68,1 -12.43% | -61,7 -72,6 15% | -75,2 -78,1 3.71% | -109 -88,9 -22.33% | -123 -115 -7.3% | -180 -129 -39.54% | -140 | -145 | -152 | -158 | -162 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -52,7 -47,1 -11.74% | -57,6 -57,4 -0.38% | -61,2 -63,2 3.19% | -73,6 -67,8 -8.66% | -56,6 -72,3 21.63% | -68,1 -77,5 12.18% | -98,3 -86,2 -14.03% | -112 -109 -2.58% | -161 -117 -37.59% | -120 | -126 | -134 | -141 | -139 |
|
Net income Million USD | Released Forecast Spread | -52,7 -48,2 -9.36% | -57,6 -59,0 2.24% | -61,2 -63,6 3.69% | -73,3 -69,8 -5.05% | -56,5 -70,9 20.25% | -68,1 -78,0 12.66% | -98,3 -86,8 -13.28% | -108 -110 1.61% | -162 -120 -34.59% | -121 | -126 | -134 | -140 | -141 |
|
EPS USD | Released Forecast Spread | -0,71 -0,65 -8.66% | -0,78 -0,79 1.76% | -0,82 -0,86 4.16% | -0,87 -0,85 -2.71% | -0,63 -0,81 22.36% | -0,72 -0,82 11.69% | -0,92 -0,83 -10.65% | -0,99 -1,02 2.53% | -1,14 -0,86 -32.31% | -0,75 | -0,78 | -0,82 | -0,85 | -0,87 |
| Announcement Date | 28/02/22 | 09/05/22 | 09/08/22 | 07/11/22 | 27/02/23 | 08/05/23 | 08/08/23 | 06/11/23 | 26/02/24 | - | - | - | - | - |
More events
Past sector events for Revolution Medicines, Inc.
| 26/04/2024 | GEMPHARMATECH CO., LTD.: Q1 2024 Earnings Release |
| 26/04/2024 | GEMPHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 26/04/2024 06:00 | BB BIOTECH AG: Q1 2024 Earnings Release |
| 25/04/2024 | BIDE PHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 25/04/2024 | PHARMARESOURCES (SHANGHAI) CO., LTD.: Q1 2024 Earnings Release |
| 25/04/2024 | HINOVA PHARMACEUTICALS INC.: Q1 2024 Earnings Release (Projected) |
| 25/04/2024 | BEIJING SUN-NOVO PHARMACEUTICAL RESEARCH CO., LTD.: Q4 2023 Earnings Release |
| 25/04/2024 | CHEMPARTNER PHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 25/04/2024 12:00 | MORPHIC HOLDING, INC.: Q1 2024 Earnings Release |
| 25/04/2024 07:00 | PURETECH HEALTH PLC: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- RVMD Stock
- Calendar Revolution Medicines, Inc.
